EU panel backs approval of Pfizer's leukemia drug Bosulif

The European Medicines Agency's Committee for Medicinal Products for Human Use recommended that Pfizer's Bosulif, or bosutinib, be approved to treat patients with Philadelphia chromosome-positive chronic myelogenous leukemia who didn't respond to or can't tolerate other treatments. The drug, a tyrosine kinase inhibitor, was cleared by the FDA in September.

View Full Article in:

Pharmaceutical Business Review Online · Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA